낭포성 섬유증 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cystic Fibrosis Therapeutics Market size is expected to reach USD 86.23 Billion in 2034 from USD 22.55 Billion (2025) growing at a CAGR of 16.07% during 2026-2034.

The Global Cystic Fibrosis Therapeutics Market is growing steadily due to increasing awareness of the disease and advancements in targeted therapies. Cystic fibrosis is a genetic disorder that primarily affects the lungs and digestive system, requiring long-term treatment and management. Pharmaceutical companies are investing heavily in research and development to introduce innovative therapies that address the underlying genetic mutations responsible for the condition, improving patient outcomes and life expectancy.

A major driver of market growth is the development of CFTR modulator therapies, which target the root cause of cystic fibrosis rather than simply managing symptoms. These advanced treatments have transformed the treatment landscape and significantly improved the quality of life for many patients. Additionally, improved diagnostic techniques and newborn screening programs are helping detect the disease earlier, enabling timely treatment and increasing demand for effective therapeutics.

In the coming years, the market is expected to benefit from continued research into gene therapies and personalized medicine approaches. Advances in biotechnology may lead to more precise treatments that correct the genetic defects responsible for cystic fibrosis. Furthermore, increasing healthcare investments and supportive regulatory frameworks are likely to accelerate drug development, making advanced therapies more accessible to patients worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• CFTR Modulators
• Pancreatic Enzyme Supplements
• Mucolytics
• Bronchodilators

By Route of Administration

• Oral
• Inhaled

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AbbVie Inc, F HoffmannLa Roche Ltd, Gilead, Novartis AG, Vertex Pharmaceuticals Incorporated, AIT Advanced Inhalation Therapies, Alaxia, Teva Pharmaceutical Industries Ltd, Merck amp Co Inc, Sionna Therapeutics, Alcresta Therapeutics Inc, AstraZeneca
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. CFTR Modulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Pancreatic Enzyme Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Mucolytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Bronchodilators Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Inhaled Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CYSTIC FIBROSIS THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc
  • 9.2.2 F. Hoffmann-La Roche Ltd
  • 9.2.3 Gilead
  • 9.2.4 Novartis AG
  • 9.2.5 Vertex Pharmaceuticals Incorporated
  • 9.2.6 AIT (Advanced Inhalation Therapies)
  • 9.2.7 Alaxia
  • 9.2.8 Teva Pharmaceutical Industries Ltd
  • 9.2.9 Merck & Co. Inc
  • 9.2.10 Sionna Therapeutics
  • 9.2.11 Alcresta Therapeutics Inc
  • 9.2.12 AstraZeneca